PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Frontiers in Immunology0 citationsOpen Access

Functional characterization and clinical significance of IGSF8 in pan-cancer: an integrated bioinformatic and experimental study

View Full Paper
JWJie WangLLLingxiao LuRWRuicheng Wu

Key Points

  • IGSF8 is significantly upregulated in 23 cancer types, indicating a potential role in tumor progression and poor patient prognosis.
  • Analysis revealed strong correlations between IGSF8 expression and immune checkpoint genes, highlighting its involvement in immune responses.
  • The study utilized comprehensive bioinformatics approaches and experimental assays to assess IGSF8's clinical significance across multiple cancers.
  • Research identified drug sensitivity of cancer cells to BX-795 and tozasertib, offering insights into potential targeted treatments.

Abstract

Background Immunoglobulin superfamily member 8 (IGSF8) is a membrane protein implicated in crucial biological processes like cell interactions and immune responses. Emerging evidence suggests that IGSF8 plays a significant role in various cancers by influencing tumor progression through regulation of cell proliferation, migration, and apoptosis. Analyzing its expression, mutation status, and clinical correlations across different cancer types through pan-cancer bioinformatics could provide valuable insights into its potential as a biomarker and target for cancer therapies. Methods In this study, we utilized several public databases to investigate the biological role of IGSF8, focusing on its associations with prognosis, tumor heterogeneity, stemness, immune checkpoint genes, and immune cell infiltration across different types of cancer. Additionally, the GDSC and CTRP databases were employed to assess the sensitivity of IGSF8 to small molecule drugs. CCK8 assay and colony formation assay were used to detect its biological effect on cancer cells. Results IGSF8 was significantly upregulated in 23 types of cancers and associated with poor prognosis in several cancers, including cell carcinoma and endocervical adenocarcinoma (CESC) and Acute Myeloid Leukemia(LAML). Its high expression was linked to multiple immune regulatory genes and immune checkpoint genes in the tumor microenvironment, with a notable positive correlation with CD276 in most cancers. IGSF8 was also closely associated with multiple indicators of tumor heterogeneity, stemness, as well as significant RNA methylation modifications across various cancers. Drug sensitivity analysis identified BX-795 and tozasertib as potential treatments for tumors with high IGSF8 expression. Knockdown of IGSF8 significantly inhibited the proliferation ability of prostate cancer cells. Conclusion Our findings indicated that IGSF8 might be used as a potential prognostic marker and therapeutic target for various cancers.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68c1d24654b1d3bfb60f85b6https://doi.org/10.3389/fimmu.2025.1642193
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IGSF8 is a potential target for the treatment of Gliomas2024 · 3 citations
  2. 2IGSF8 (CD316) defines a distinct transcriptional phenotype independent of immune infiltration in lung adenocarcinoma: An integrative immunogenomic analysis2026
  3. 3Abstract 3914: IGSF8 is a novel innate immune checkpoint and cancer immunotherapy target2024 · 1 citations
  4. 4P53 Inhibition Diminishes IGSF9 Gene Activity to Promote DNA Repair and Exacerbate the Progression of Colon Cancer2026
  5. 5Abstract CT001: Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study2026